Autolus Therapeutics (NASDAQ:AUTL) Shares Up 11.9%
Autolus Therapeutics Ltd – (NASDAQ:AUTL)’s stock price shot up 11.9% on Monday . The stock traded as high as $15.82 and last traded at $15.38, 128,906 shares changed hands during trading. An increase of 34% from the average session volume of 96,501 shares. The stock had previously closed at $13.75.
Several research firms have weighed in on AUTL. HC Wainwright set a $18.00 target price on Sutro Biopharma and gave the company a “buy” rating in a research note on Friday, May 17th. Zacks Investment Research raised General Moly from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. Finally, William Blair began coverage on American Software in a research note on Wednesday, April 3rd. They set an “outperform” rating and a $12.03 target price on the stock.
The company has a debt-to-equity ratio of 0.12, a quick ratio of 10.66 and a current ratio of 10.66. The stock’s 50 day moving average price is $15.69. The firm has a market capitalization of $552.01 million and a P/E ratio of -10.83.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP grew its stake in shares of Autolus Therapeutics by 93.4% in the 1st quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock valued at $7,330,000 after buying an additional 112,489 shares in the last quarter. BlackRock Inc. grew its stake in shares of Autolus Therapeutics by 4,011.3% in the 4th quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock valued at $6,666,000 after buying an additional 198,036 shares in the last quarter. CWM LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter valued at approximately $1,105,000. Geode Capital Management LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $322,000. Finally, Barclays PLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $113,000. 43.38% of the stock is owned by institutional investors and hedge funds.
About Autolus Therapeutics (NASDAQ:AUTL)
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Featured Article: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.